CompletedNot applicableNCT03517462
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
Studying Onchocerciasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Washington University School of Medicine
- Principal Investigator
- Gary Weil, MDWashington University School of Medicine
- Intervention
- Ivermectin 3Mg Tab(drug)
- Enrollment
- 231 enrolled
- Eligibility
- 16-70 years · All sexes
- Timeline
- 2018 – 2019
Study locations (1)
- University of Health and Allied Sciences, Hohoe, Ghana
Collaborators
Case Western Reserve University · University of Health and Allied Sciences
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03517462 on ClinicalTrials.govOther trials for Onchocerciasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06350851Development of a New Rapid Diagnostic Test to Support Onchocerciasis EliminationBioaster
- ACTIVE NOT RECRUITINGPHASE2NCT05180461Emodepside Phase II Trial for Treatment of OnchocerciasisDrugs for Neglected Diseases
- ACTIVE NOT RECRUITINGPHASE3NCT03876262Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for OnchocerciasisMedicines Development for Global Health